France Thrombosis And Hemostasis Biomarkers Market Size & Outlook

The thrombosis and hemostasis biomarkers market in France is expected to reach a projected revenue of US$ 245.0 million by 2030. A compound annual growth rate of 7.1% is expected of France thrombosis and hemostasis biomarkers market from 2023 to 2030.
Revenue, 2022 (US$M)
$141.9
Forecast, 2030 (US$M)
$245.0
CAGR, 2023 - 2030
7.1%
Report Coverage
France

France thrombosis and hemostasis biomarkers market, 2018-2030 (US$M)

France

Related Markets

France thrombosis and hemostasis biomarkers market highlights

  • The France thrombosis and hemostasis biomarkers market generated a revenue of USD 141.9 million in 2022 and is expected to reach USD 245.0 million by 2030.
  • The France market is expected to grow at a CAGR of 7.1% from 2023 to 2030.
  • In terms of segment, reagents & consumables was the largest revenue generating product in 2022.
  • Reagents & Consumables is the most lucrative product segment registering the fastest growth during the forecast period.


Thrombosis and hemostasis biomarkers market data book summary

Market revenue in 2022USD 141.9 million
Market revenue in 2030USD 245.0 million
Growth rate7.1% (CAGR from 2022 to 2030)
Largest segmentReagents & consumables
Fastest growing segmentReagents & Consumables
Historical data2018 - 2021
Base year2022
Forecast period2023 - 2030
Quantitative unitsRevenue in USD million
Market segmentationAnalyzers, Reagents & Consumables
Key market players worldwideBioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories


Other key industry trends

  • In terms of revenue, France accounted for 2.8% of the global thrombosis and hemostasis biomarkers market in 2022.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany thrombosis and hemostasis biomarkers market is projected to lead the regional market in terms of revenue in 2030.
  • France is the fastest growing regional market in Europe and is projected to reach USD 245.0 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Thrombosis And Hemostasis Biomarkers Market Scope

Thrombosis and hemostasis biomarkers market segmentation & scope
Analyzers
Reagents & Consumables
Clinical Laboratory Tests
Point-of-Care Tests
D-Dimer
Anti-Thrombin III
Plasminogen
Soluble Fibrin
Selectins
Factor VIII
PT
APTT
Fibrinogen
Others
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Disseminated Intravascular Coagulation (DIC)
Others
Hospitals & Clinics
Academic & Research Institutes
Diagnostic Centers
Others

Thrombosis And Hemostasis Biomarkers Market Companies

Name Profile # Employees HQ Website

France thrombosis and hemostasis biomarkers market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.


Reagents & consumables was the largest segment with a revenue share of 65.26% in 2022. Horizon Databook has segmented the France thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.


Increasing prevalence of blood clotting disorders in the population, growing healthcare spending, and the availability of diagnostic tests & treatments are expected to boost the country’s market. The increasing geriatric population and rising chronic diseases are contributing to the further growth of the market.

Thrombosis and hemostasis biomarkers serve as diagnostic & monitoring tools for different blood clotting conditions, such as DVT & PE. These biomarkers aid in identifying patients who are at high risk of developing blood clots and track the efficacy of the treatments.

For instance, according to the BMC Journal, the estimated incidence of VTE in France is 184.0 per 100,000 population, and the incidence of PE is 64.2 per 100,000 population. Some of the key players in the market are Roche Diagnostics, Siemens Healthcare, and Abbott Laboratories.

Reasons to subscribe to France thrombosis and hemostasis biomarkers market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of France thrombosis and hemostasis biomarkers market databook

  • Our clientele includes a mix of thrombosis and hemostasis biomarkers market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the France thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into France thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

France thrombosis and hemostasis biomarkers market size, by product, 2018-2030 (US$M)

France Thrombosis And Hemostasis Biomarkers Market Outlook Share, 2022 & 2030 (US$M)

France thrombosis and hemostasis biomarkers market size, by product, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more